Acumen Pharmaceuticals, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 52.37 million compared to USD 42.86 million a year ago. Basic loss per share from continuing operations was USD 1.08 compared to USD 1.06 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.17 USD | -0.63% | +0.63% | -17.45% |
Apr. 04 | Acumen Pharmaceuticals Signs Deal With Lonza to Manufacture Alzheimer's Treatment Drug | MT |
Apr. 04 | Lonza Enters Manufacturing Agreement for Acumen’s Alzheimer’s Disease Drug Candidate | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.45% | 190M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- ABOS Stock
- News Acumen Pharmaceuticals, Inc.
- Acumen Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023